Pfizer Inc

Pfizer’s San Diego R&D consolidation and cost‑cutting plan aim to offset patent cliffs, boost margins, and accelerate GLP‑1 and antibody‑drug conjugate launches amid rising institutional interest.

Pfizer’s low valuation, strong earnings, GLP‑1 pipeline, and tariff‑exemption strategy make it a value‑driven pick amid evolving drug‑tariff rules.

Pfizer’s €1.9 billion court ruling, trial pause, and ViiV divestiture illustrate how the pharma giant balances legal risks, enrollment challenges, and strategic growth to protect cash flow, patient access, and high‑margin portfolio value.

Pfizer’s latest earnings beat forecasts, driven by strong immunology and oncology sales, while ETF inflows boost confidence. Discover how its haemophilia pipeline and fusion‑protein platform could reshape revenue and keep investors wary of exec‑stoc…

Pfizer’s latest corporate moves: phantom‑stock conversion aligns executive ownership, Fc‑fusion biologics lead in trials, and legal tech cuts litigation costs.

Pfizer’s Q4 earnings beat, strong oncology pipeline and strategic M&A plans position it to weather patent cliffs and capture growth in the competitive drug market.

Pfizer shares surge after analyst upgrade and promising phase‑II breast‑cancer data for PF‑Lym‑210, highlighting strong pipeline and solid earnings growth.

Pfizer’s latest atirmociclib phase‑two results spark optimism while its ambitious 20‑trial pipeline and strong cash flow shape long‑term strategy, revealing key risks and investment insights.

FTC eyes drug makers as key patents expire, aiming to cut price spikes and speed generic entry while protecting innovation.

Pfizer CEO Albert Bourla boosts his stake by converting phantom stock units into shares, showing how pharma leaders align incentives with shareholder value.